Moderna announced today that its COVID-19 vaccine produces “robust” levels of antibodies among children six months to six years old similar to those generated by adults vaccinated with the shot.
The results are part of the company’s KidCOVE study and will be submitted to the Food and Drug Administration (FDA) for emergency use authorization in this youngest, and last gro…
Read more